TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

HUMALOG TEMPO PEN

INSULIN LISPRO RECOMBINANT
Approved 1996-06-14
6
Indications
--
Phase 3 Trials
29
Years on Market

Details

Status
Prescription
First Approved
1996-06-14
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: INSULIN LISPRO RECOMBINANT

HUMALOG TEMPO PEN Approval History

Loading approval history...

What HUMALOG TEMPO PEN Treats

1 indications

HUMALOG TEMPO PEN is approved for 1 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Diabetes
Source: FDA Label

Drugs Similar to HUMALOG TEMPO PEN

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADMELOG
INSULIN LISPRO
1 shared
SANOFI-AVENTIS US
Shared indications:
Diabetes
ADMELOG SOLOSTAR
INSULIN LISPRO
1 shared
SANOFI-AVENTIS US
Shared indications:
Diabetes
AFREZZA
INSULIN RECOMBINANT HUMAN
1 shared
MANNKIND
Shared indications:
Diabetes
APIDRA
INSULIN GLULISINE RECOMBINANT
1 shared
Sanofi
Shared indications:
Diabetes
APIDRA SOLOSTAR
INSULIN GLULISINE RECOMBINANT
1 shared
Sanofi
Shared indications:
Diabetes
BAQSIMI
GLUCAGON
1 shared
AMPHASTAR PHARMS INC
Shared indications:
Diabetes
FIASP
INSULIN ASPART
1 shared
Novo Nordisk
Shared indications:
Diabetes
FIASP FLEXTOUCH
INSULIN ASPART
1 shared
Novo Nordisk
Shared indications:
Diabetes
FIASP PENFILL
INSULIN ASPART
1 shared
Novo Nordisk
Shared indications:
Diabetes
FLOLIPID
SIMVASTATIN
1 shared
SALERNO PHARMS
Shared indications:
Diabetes
GVOKE VIALDX
GLUCAGON
1 shared
XERIS
Shared indications:
Diabetes
HUMALOG
INSULIN LISPRO RECOMBINANT
1 shared
Eli Lilly
Shared indications:
Diabetes
HUMALOG KWIKPEN
INSULIN LISPRO RECOMBINANT
1 shared
Eli Lilly
Shared indications:
Diabetes
HUMULIN R KWIKPEN
INSULIN HUMAN
1 shared
Eli Lilly
Shared indications:
Diabetes
KIRSTY
INSULIN ASPART-XJHZ
1 shared
BIOCON BIOLOGICS INC
Shared indications:
Diabetes
LANTUS
INSULIN GLARGINE RECOMBINANT
1 shared
Sanofi
Shared indications:
Diabetes
LANTUS SOLOSTAR
INSULIN GLARGINE RECOMBINANT
1 shared
Sanofi
Shared indications:
Diabetes
LEVEMIR
INSULIN DETEMIR
1 shared
Novo Nordisk
Shared indications:
Diabetes
LYUMJEV
INSULIN LISPRO-AABC
1 shared
Eli Lilly
Shared indications:
Diabetes
MERILOG
INSULIN ASPART-SZJJ
1 shared
SANOFI-AVENTIS U.S. LLC
Shared indications:
Diabetes
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

HUMALOG TEMPO PEN FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.